<DOC>
	<DOCNO>NCT00055770</DOCNO>
	<brief_summary>Phase I/II trial study effectiveness combine erlotinib docetaxel treat patient locally advance , recurrent , metastatic head neck cancer . Erlotinib may stop growth tumor cell block enzymes necessary growth . Drugs use chemotherapy work different way stop tumor cell divide stop grow die . Combining erlotinib docetaxel may kill tumor cell .</brief_summary>
	<brief_title>Erlotinib Plus Docetaxel Treating Patients With Locally Advanced , Metastatic , Recurrent Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose dose-limiting toxicity erlotinib administer combination docetaxel patient locally advance , metastatic , recurrent squamous cell carcinoma head neck . II . Determine response rate , duration response , time progression , survival patient treat regimen . III . Determine pharmacokinetics regimen patient . IV . Correlate presence PTEN , RB , P-Akt , p15 , p16 , cyclin D1 , p27 , p53 gene tumor tissue response patient treat regimen . OUTLINE : This phase I , dose-escalation study erlotinib follow phase II study . PHASE I : Patients receive oral erlotinib daily day 1-28 docetaxel IV 1 hour day 8 , 15 , 22 . Treatment repeat every 28 day total 6 course absence disease progression unacceptable toxicity . Patients receive escalate dos erlotinib maximum tolerate dose ( MTD ) determine . The MTD define dose 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional cohort 6 patient receive erlotinib MTD . PHASE II : Patients receive erlotinib MTD docetaxel phase I .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Laryngeal Diseases</mesh_term>
	<mesh_term>Laryngeal Neoplasms</mesh_term>
	<mesh_term>Oropharyngeal Neoplasms</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Salivary Gland Neoplasms</mesh_term>
	<mesh_term>Paranasal Sinus Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically cytologically confirm squamous cell carcinoma head neck meet 1 follow stag criterion : Recurrent Metastatic Locally advance determine incurable surgery radiotherapy Measurable disease No known brain metastasis Performance status ECOG 02 Performance status Karnofsky 60100 % WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Bilirubin normal AST ALT great 2.5 time upper limit normal Creatinine normal Creatinine clearance least 60 mL/min No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No severe pulmonary insufficiency , include chronic obstructive pulmonary disease , require oxygen ( O2 saturation le 90 % ) and/or increase PaCO2 blood gas level great 50 mm Hg No history abnormality cornea ( e.g. , dry eye syndrome Sj√∂gren 's syndrome ) No congenital abnormality ( e.g. , Fuch 's dystrophy ) No abnormal slitlamp examination use vital dye ( e.g. , fluorescein BengalRose ) No abnormal corneal sensitivity test ( Schirmer test similar tear production test ) Able take oral medication No requirement IV alimentation No active peptic ulcer disease Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No significant traumatic injury within past 21 day No prior allergic reaction compound similar chemical biological composition study drug No grade 2 great persistent peripheral neuropathy No concurrent uncontrolled illness would preclude study participation No ongoing active infection No psychiatric illness social situation would preclude study compliance No prior immunotherapy head neck cancer No 1 prior chemotherapy regimen adjuvant neoadjuvant set No 1 prior chemotherapy regimen metastatic disease No prior docetaxel ( phase II ) More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No prior hormonal therapy head neck cancer Prior external beam radiotherapy allow At least 4 week since prior radiotherapy recover More 21 day since prior major surgery No prior surgery affect gastrointestinal absorption No prior epidermal growth factor receptortargeting therapy No concurrent investigational agent No concurrent anticancer therapy agents No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>